애넥손(ANNX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $4.23 (+1.44%), 시가총액 $0.85B, 52주 최저~최고 $1.97 ~ $6.96.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical tri
애넥손의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
애넥손의 현재 주가는 $4.23 (+1.44%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
애넥손의 시가총액은 약 $0.85B입니다.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-lengt